Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Av Barcelona, Campus Vida, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain.
Department of Biochemistry and Molecular Biology, Universidade de Santiago de Compostela, Plaza do Obradoiro s/n, Santiago de Compostela, Spain.
Purinergic Signal. 2023 Jun;19(2):345-352. doi: 10.1007/s11302-022-09867-1. Epub 2022 May 5.
Conventionally, ATP is considered to be the principal energy source in cells. However, over the last few years, a novel role for ATP as a potent extracellular signaling molecule and the principal source of extracellular pyrophosphate, the main endogenous inhibitor of vascular calcification, has emerged. A large body of evidence suggests that two principal mechanisms are involved in the initiation and progression of ectopic calcification: high phosphate concentration and pyrophosphate deficiency. Pathologic calcification of cardiovascular structures, or vascular calcification, is a feature of several genetic diseases and a common complication of chronic kidney disease, diabetes, and aging. Previous studies have shown that the loss of function of several enzymes and transporters involved in extracellular ATP/pyrophosphate metabolism is associated with vascular calcification. Therefore, pyrophosphate homeostasis should be further studied to facilitate the design of novel therapeutic approaches for ectopic calcification of cardiovascular structures, including strategies to increase pyrophosphate concentrations by targeting the ATP/pyrophosphate metabolism cycle.
传统上,ATP 被认为是细胞中的主要能量来源。然而,在过去的几年中,ATP 作为一种有效的细胞外信号分子和主要的细胞外焦磷酸盐来源的新作用已经出现,焦磷酸盐是血管钙化的主要内源性抑制剂。大量证据表明,两种主要机制参与了异位钙化的发生和进展:高磷酸盐浓度和焦磷酸盐缺乏。心血管结构的病理性钙化,或血管钙化,是几种遗传疾病的特征,也是慢性肾病、糖尿病和衰老的常见并发症。先前的研究表明,参与细胞外 ATP/焦磷酸盐代谢的几种酶和转运体的功能丧失与血管钙化有关。因此,应该进一步研究焦磷酸盐的动态平衡,以促进设计针对心血管结构异位钙化的新型治疗方法,包括通过靶向 ATP/焦磷酸盐代谢循环来增加焦磷酸盐浓度的策略。